GSDME基因敲除Hela细胞
货号:
EDJ-KQ20087
物种:
人
细胞名称:
HeLa
基因名称:
GSDME
基因ID:
1687
规格:
1×10⁶cells
GSDME基因敲除细胞Hela是由艾迪基因优化的CRISPR/Cas9编辑而成,采用Sanger测序法验证敲除,保证单克隆,活性良好。
| 货号 | EDJ-KQ20087 |
|---|---|
| 产品名称 | GSDME Knockout Hela Cell Line |
| 细胞 | Hela |
| Cellosaurus ID | CVCL_0030 |
| 细胞别名 | HELA, Hela, He La, He-La, HeLa-CCL2, Henrietta Lacks cells, Helacyton gartleri |
| 基因 | GSDME |
| 基因ID | |
| 基因别名 | DFNA5|ICERE-1 |
| 摘要 |
Hearing impairment is a heterogeneous condition with over 40 loci described. The protein encoded by this gene is expressed in fetal cochlea, however, its function is not known. Nonsyndromic hearing impairment is associated with a mutation in this gene. Three transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
|
| 癌症类型 | Cervical Carcinoma |
| 细胞形态 | Adherent |
| 传代比率 | 1/5, 2days |
| 完全培养基 | MEM + 10% FBS |
| 冻存培养基 | 70%完全培养基+ 20% FBS+ 10% DMSO |
* 仅供科研使用,不适用于人体或动物,包括临床、治疗或诊断用途。
| Loci | 送检细胞STR信息 送检细胞名: HeLa | 细胞库细胞STR信息 细胞库细胞名: HeLa | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | X | ||
| CSF1PO | 9 | 10 | 9 | 10 |
| D1S1656 | 12 | 15 | 12 | 15 |
| D2S1338 | 17 | 17 | ||
| D3S1358 | 15 | 18 | 15 | 18 |
| D5S818 | 11 | 12 | 11 | 12 |
| D6S1043 | 18 | 18 | ||
| D7S820 | 8 | 12 | 8 | 12 |
| D8S1179 | 12 | 13 | 12 | 13 |
| D12S391 | 20 | 25 | 20 | 25 |
| D13S317 | 12 | 14 | 12 | 14 |
| D16S539 | 9 | 10 | 9 | 10 |
| D18S51 | 16 | 16 | ||
| D19S433 | 13 | 14 | 13 | 14 |
| D21S11 | 27 | 28 | 27 | 28 |
| FGA | 18 | 21 | 18 | 21 |
| Penta D | 8 | 15 | 8 | 15 |
| Penta E | 7 | 17 | 7 | 17 |
| TPOX | 8 | 12 | 8 | 12 |
| VWA | 16 | 18 | 16 | 18 |
* 该细胞系与收录于ATCC, DSMZ, JCRB 和 RIKEN数据库的细胞系STR数据匹配。
结论:该细胞 STR 鉴定正确。
结论:该细胞 STR 鉴定正确。
* 研究用途免责声明:本内容基于公开的研究数据、生物信息学资源及计算分析生成,仅供研究参考。
相关研究文献
Caerin 1.1 / 1.9 在 HeLa 细胞肿瘤模型中干扰 KHDRBS1 - DDX5 调节轴诱导 IL - 18 介导的细胞焦亡。
IF=3.9
Scientific reports
Cervical cancer remains a significant global health challenge, particularly in developing countries where access to HPV vaccination is limited. We previously demonstrated that caerin 1.1/1.9 (F1F3) peptides inhibit tumour growth in vitro and in vivo by inducing pyroptosis, followed by apoptosis and immune activation. In this study, we elucidate the molecular mechanisms underlying F1F3-induced pyroptosis in HeLa cells. Our results show that F1F3 triggers pyroptosis independently of GSDME, as evidenced by comparable IL-18 and LDH release in both wild type and GSDME knockout cells. Cross-linking mass spectrometry identified the interaction of F1 to KHDRBS1 and F3 to DDX5, respectively. Knockout of either KHDRBS1 or DDX5 enhanced HeLa cell sensitivity to F1F3 and significantly elevated IL-18 secretion. Notably, KHDRBS1-deficint tumours displayed accelerated growth yet responded more robustly to F1F3 treatment, suggesting a context-dependent tumour-suppressive role of KHDRBS1. These findings uncover a previously uncharacterised pathway regulated by KHDRBS1-DDX5 and demonstrate that F1F3 can effectively interfere with this axis to induce anti-tumour immune responses, highlighting their potential as novel therapeutic agents for cervical cancer.
该敲除模型可用于:
- 研究GSDME在HeLa细胞肿瘤模型中诱导细胞焦亡的作用。
- 研究KHDRBS1-DDX5调节轴下游的IL-18介导的细胞焦亡通路。
- 评估抗肿瘤肽如Caerin 1.1/1.9的作用机制。
- 在程序性细胞死亡试验中验证GSDME作为关键效应子的功能。
- 筛选调节宫颈癌研究中GSDME依赖性细胞焦亡的化合物或遗传因子。